Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA Report Highlights More Than 250 Vaccines in Development

Vaccine kidWashington, DC, December 31, 2016 — Hannah Mooney writes on the Pharmaceutical Research and Manufacturers of America’s (PhRMA) blog, The Catalyst, that, more than 200 years ago, the first vaccine was developed for smallpox, and now, the disease has been eradicated worldwide.

In addition, in the United States, the transmission of poliovirus, measles and rubella have been eliminated.

These are examples of tremendous scientific progress, and through our growing understanding of how these and other diseases work at the molecular level, many new therapeutic and preventative vaccines have been developed.

A new PhRMA report, “Medicines in Development for Vaccines,” offers insight into the more than 250 vaccines currently in development, designed to prevent and treat illness.

More than two-thirds of the vaccines in the last 25 years have been developed in the United States – underscoring the commitment of America’s biopharmaceutical research companies despite a particularly challenging research and development process.

Vaccines in development today will help prevent or treat a number of conditions, including:

  • 124 for infectious diseases; and
  • 105 for cancer.

Thanks to the perseverance of researchers and scientists, patients are reaping the benefits of innovative medicines to protect against many more life-threatening diseases in years to come.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.

To visit PhRMA’s information-packed, consumer-friendly blog about the innovation-driven biopharmaceutical industry, The Catalyst, click here.